Belpointe Asset Management LLC Increases Stake in Eli Lilly and Company $LLY

Belpointe Asset Management LLC raised its position in shares of Eli Lilly and Company (NYSE:LLY) by 21.0% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 5,671 shares of the company’s stock after purchasing an additional 986 shares during the quarter. Belpointe Asset Management LLC’s holdings in Eli Lilly and Company were worth $4,422,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in LLY. WestEnd Advisors LLC lifted its stake in shares of Eli Lilly and Company by 210.0% in the first quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock worth $26,000 after buying an additional 21 shares in the last quarter. Wealth Preservation Advisors LLC purchased a new stake in Eli Lilly and Company in the first quarter valued at $27,000. Citizens National Bank Trust Department lifted its position in Eli Lilly and Company by 180.0% in the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company’s stock valued at $35,000 after buying an additional 27 shares during the last quarter. Financial Gravity Asset Management Inc. acquired a new stake in Eli Lilly and Company in the 1st quarter valued at approximately $40,000. Finally, TD Capital Management LLC raised its holdings in shares of Eli Lilly and Company by 129.2% in the 1st quarter. TD Capital Management LLC now owns 55 shares of the company’s stock valued at $46,000 after buying an additional 31 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Insiders Place Their Bets

In other Eli Lilly and Company news, EVP Daniel Skovronsky purchased 1,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 12th. The shares were purchased at an average cost of $634.40 per share, with a total value of $634,400.00. Following the completion of the transaction, the executive vice president owned 137,660 shares of the company’s stock, valued at approximately $87,331,504. This represents a 0.73% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Jamere Jackson acquired 200 shares of the company’s stock in a transaction on Friday, August 8th. The stock was bought at an average price of $639.56 per share, for a total transaction of $127,912.00. Following the purchase, the director owned 9,402 shares in the company, valued at approximately $6,013,143.12. This trade represents a 2.17% increase in their position. The disclosure for this purchase can be found here. Insiders bought a total of 4,514 shares of company stock valued at $2,894,841 over the last 90 days. 0.13% of the stock is owned by corporate insiders.

Eli Lilly and Company Trading Up 2.5%

Shares of NYSE LLY opened at $840.46 on Monday. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $937.00. The stock’s 50 day moving average price is $734.60 and its two-hundred day moving average price is $765.44. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. The stock has a market capitalization of $795.46 billion, a P/E ratio of 54.93, a PEG ratio of 1.17 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping the consensus estimate of $5.59 by $0.72. The business had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company’s quarterly revenue was up 37.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have weighed in on LLY shares. Deutsche Bank Aktiengesellschaft cut their price target on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating on the stock in a report on Monday, August 11th. Leerink Partnrs cut Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 7th. Leerink Partners restated a “market perform” rating and issued a $715.00 target price on shares of Eli Lilly and Company in a research note on Thursday, August 7th. Cantor Fitzgerald cut their price objective on Eli Lilly and Company from $975.00 to $825.00 and set an “overweight” rating for the company in a research report on Wednesday, August 13th. Finally, HSBC upped their target price on Eli Lilly and Company from $700.00 to $800.00 in a report on Wednesday, October 1st. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and ten have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $938.94.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.